CN1328092A - Process for extracting tea pigment and its application in treating hyperlipomia - Google Patents
Process for extracting tea pigment and its application in treating hyperlipomia Download PDFInfo
- Publication number
- CN1328092A CN1328092A CN00116395A CN00116395A CN1328092A CN 1328092 A CN1328092 A CN 1328092A CN 00116395 A CN00116395 A CN 00116395A CN 00116395 A CN00116395 A CN 00116395A CN 1328092 A CN1328092 A CN 1328092A
- Authority
- CN
- China
- Prior art keywords
- tea pigment
- treatment
- ldl
- hyperlipomia
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
A process for extracting tea pigment features the combination of immersion, extraction and column separation for high purity and complete active components. The extract contains theaflavin, theaproten, theabrown and catechin and can be used to reduce blood fat
Description
The invention provides a kind of method of from tealeaves, extracting tea pigment.This tea pigment contains theoflavin, thearubigins, theabrownin and catechin.
Method
1, tealeaves is mixed with (W/W is 1: 10) with 80% ethanolic soln, soaking at room temperature 2 hours, reflux 1 hour removes by filter tealeaf residue.
2, the hydrochloric acid conditioning solution pH value of adding 1mol/L is 3.2 in the filtrate, and room temperature was placed 30 minutes, and centrifugal 30 minutes of 10000rpm abandons precipitation.
3, getting the sodium hydrate regulator solution pH value that supernatant liquor adds 1mol/L is 7.0, is splined on sephadex column (Sephadex LH-20), and the ethanolic soln with 40%-100% carries out wash-out.
4, the pH value of the sodium hydrate regulator solution of elutriant adding 1mol/L is 8.0, and the adding methylene dichloride extracts.Remove water, wave diffusing solvent for 40 ℃, promptly obtain the tea pigment powder.Pharmacological experiment 1, experimentation on animals (1) security test
This extract tea pigment is irritated stomach with 100 times of human dosage to rat, observe a week, do not see that rat has abnormal conditions.The result shows, this extract safety non-toxic.(2) reducing blood lipid
The hyperlipemia rat animal model is raised with this extract tea pigment.After 1 month, compare, observe every index with control group.Tea pigment shows result's (seeing accompanying drawing 1) of the therapeutic action of hyperlipemia rat, compares with control group, observes every index.The result shows that this extract can effectively reduce total cholesterol in the blood (TC), reduces low-density lipoprotein (LDL), the effect of triglyceride reducing (TG) and high density lipoprotein increasing (LDL).2, human experimentation (1) is to the effect of hyperlipidemia
Below be normal people's TC, TG, HDL, the LDL value:
TC?????3.1?—5.7mol/L
TG?????0.56—1.7mol/L
HDL????1.04—1.55mol/L
LDL????1.80—3.36mol/L
Altogether 1,696 hyperlipidemia patient is tested.Wherein the male sex is 920,776 of women, and the age, the mean age was 58.9 ± 7.9 years old between 35 to 81 years old.Patient takes this tea pigment every day 3 times, and each 1 (125mg) obeyed for 4 weeks altogether.Tea pigment is seen accompanying drawing 2 and following table 1 and 2 to hyperlipidemia patient's exercising result.
Patient need meet following standard: 1) no acute heart disease, no brain damage, wound need be after accepting other operation after at least 6 months.2) athyreosis disease 5 no kidney disease 3) non-diabetic 4)) do not have three phase hypertension 6) no drug-induced hyperlipidemia 7) Wuhuai pregnant woman woman
TC in table 1 blood, TG, HDL and LDL level
| Case load (individual) | Before the treatment (mol/L) | Treatment back (mol/L) | Velocity of variation (%) | The P value | |
| ?TC | ?811 | ?6.71±0.55 | ?5.65±0.41 | -15.8 | ＜0.01 |
| ?TG | ?923 | ?2.95±0.59 | ?2.27±0.31 | -23.1 | ＜0.01 |
| ?LDL | ?154 | ?4.05±0.37 | ?3.35±0.34 | -17.3 | ＜0.01 |
| ?HDL | ?276 | ?1.19±0.28 | ?1.34±0.19 | +12.6 | ＜0.01 |
Table 2 couple hyperlipidemia patient's treatment is efficient
(2) dosage (250mg and 125mg) and the course of treatment (60 days and 30 days) are to the influence of treatment
| Case load (individual) | Significant curative effect rate (%) | Efficient (%) | Inefficiency (%) | Total effective rate (%) | |
| ?TC | ????811 | ?59.8(485) | 12.5(101) | 27.7(225) | ????72.3 |
| ?TG | ????923 | ?41.7(385) | 24.1(222) | 34.2(316) | ????65.8 |
| ?LDL | ????154 | ?48.7(75) | 31.2(48) | 20.1(31) | ????79.9 |
| ?HDL | ????276 | ?50.7(140) | 23.9(66) | 25.4(70) | ????74.7 |
Relation
Altogether 521 hyperlipidemia patients are tested.Wherein the male sex is 310, and the women 211
Name, the age, the mean age was 55.2 ± 5.9 years old between 28 to 79 years old.
A group: every day 3 times, each 125mg
B group: every day 3 times, each 250mg
The various dose tea pigment is seen accompanying drawing 3,4 and following to hyperlipidemia patient's exercising result
Table 3 is to 6.Patient need meet following standard: 1) no acute heart disease, no brain damage, wound need be after accepting other operation after at least 6 months.2) athyreosis disease 5 no kidney disease 3) non-diabetic 4)) do not have three phase hypertension 6) no drug-induced hyperlipidemia 7) TC in women table 3 blood of Wuhuai pregnant woman, TG, course of treatment of HDL and LDL level is 30 days
| Group | Case load (individual) | Before the treatment (mol/L) | Treatment back (mol/L) | Velocity of variation (%) | The P value | |
| ????TC | ????A | ????210 | ????6.51±0.97 | ?5.51±0.76 | ????-15.4 | ????＜0.01 |
| ????B | ????156 | ????6.54±0.88 | ?5.21±0.61 | ????-20.3 | ????＜0.01 | |
| ????TG | ????A | ????198 | ????3.11±0.74 | ?2.34±0.46 | ????-24.8 | ????＜0.01 |
| ????B | ????112 | ????3.06±0.78 | ?2.01±0.71 | ????-34.3 | ????＜0.01 | |
| ????LDL | ????A | ????165 | ????4.32±0.76 | ?3.41±0.59 | ????-21.1 | ????＜0.01 |
| ????B | ????120 | ????4.26±0.81 | ?3.03±0.65 | ????-28.9 | ????＜0.01 | |
| ????HDL | ????A | ????171 | ????1.04±0.35 | ?1.23±0.29 | ????+18.3 | ????＜0.01 |
| ????B | ????104 | ????0.98±0.26 | ?1.31±0.22 | ????+33.7 | ????＜0.01 |
Table 4 couple hyperlipidemia patient's treatment is efficient
Be 30 days a course of treatment
| Group | Case load (individual) | Significant curative effect rate (%) | Efficient (%) | Inefficiency (%) | Total effective rate (%) | |
| ????TC | ?A | ????210 | ????55.2(116) | 15.2(32) | 29.6(62) | ????70.4 |
| ?B | ????156 | ????62.8(98) | 14.1(22) | 23.1(36) | ????76.9 | |
| ????TG | ?A | ????198 | ????39.9(79) | 21.2(42) | 38.9(77) | ????61.1 |
| ?B | ????112 | ????50.9(57) | 19.6(22) | 29.5(33) | ????70.5 | |
| ?LDL | ?A | ????165 | ????47.3(78) | 28.5(47) | 24.2(40) | ????75.8 |
| ?B | ????120 | ????50.8(61) | 30.0(36) | 19.2(23) | ????81.8 | |
| ?HDL | ?A | ????171 | ????49.7(85) | 21.6(37) | 28.7(49) | ????71.4 |
| ?B | ????104 | ????55.8(58) | 24.0(25) | 20.2(21) | ????79.8 |
TC in table 5 blood, TG, HDL and LDL level
Be 60 days a course of treatment
| Group | Case load (individual) | Before the treatment (mol/L) | Treatment back (mol/L) | Velocity of variation (%) | The P value | |
| TC | ?A | ????210 | ????6.51±0.97 | ????5.48±0.73 | ????-15.8 | ＜0.01 |
| ?B | ????156 | ????6.54±0.88 | ????5.14±0.75 | ????-21.4 | ＜0.01 | |
| ?TG | ?A | ????198 | ????3.11±0.74 | ????2.30±0.46 | ????-26.0 | ＜0.01 |
| ?B | ????112 | ????3.06±0.78 | ????1.92±0.53 | ????-37.2 | ＜0.01 | |
| ?LDL | ?A | ????165 | ????4.32±0.76 | ????3.38±0.46 | ????-21.8 | ＜0.01 |
| ?B | ????120 | ????4.26±0.81 | ????2.89±0.58 | ????-32.2 | ＜0.01 | |
| ?HDL | ?A | ????171 | ????1.04±0.35 | ????1.24±0.24 | ????+19.2 | ＜0.01 |
| ?B | ????104 | ????0.98±0.26 | ????1.34±0.19 | ????+36.7 | ＜0.01 |
Table 6 couple hyperlipidemia patient's treatment is efficient
Be 60 days a course of treatment
| Group | Case load (individual) | Significant curative effect rate (%) | Efficient (%) | Inefficiency (%) | Total effective rate (%) | |
| TC | ?A | ????210 | ?59.0(124) | 12.4(26) | 28.6(60) | ????71.4 |
| ?B | ????156 | ?67.9(106) | 10.3(16) | 21.8(34) | ????78.2 | |
| ?TG | ?A | ????198 | ?46.5(92) | 17.6(35) | 35.9(71) | ????64.1 |
| ?B | ?112 | ?59.8(67) | 13.4(15) | 26.8(30) | ????73.2 | |
| ?LDL | ?A | ????165 | ?57.0(94) | 20.0(33) | 23.0(38) | ????77.0 |
| ?B | ????120 | ?65.0(78) | 18.3(22) | 16.7(20) | ????83.3 | |
| ?HDL | ?A | ????171 | ?54.4(93) | 18.1(31) | 27.5(47) | ????72.5 |
| ?B | ????104 | ?59.6(62) | 21.2(22) | 19.2(20) | ????81.8 |
After taking this product, the every blood lipids index of patient all has significance to change.Yet the patient's of different course same dose result is there was no significant difference (P＞0.05) but.
Reference Relation of green tea consumption to serum lipids and lipoproteins inJapanese men, Kono S., et al, Kyushu University, Fukuoka, Japan, J.Epidemiology, 6 (3): 128-33,1996 SepGreen Tea Intake in relation to SerumLipid Levels in Middle-AgedJapanese Men and Women, Tsubono Y, Annals Epidemiology, 1997, the May tea pigment is to the therapeutic action of hyperlipidaemia, Liu Liangrong, etc., China Metallurgical Industry's medical journal, 14 (1): 9-11,1997,02,15 tea pigments are to the observation of curative effect of hyperlipidaemia, tea pigment clinical study cooperative groups, modern diagnosis and treatment, 8 (4): 211-213,1997,07,15 modern diagnosis and treatment, the 6th volume (supplementary issue), 1996
Claims (3)
1. experiment shows that the tea pigment for preparing by the method among the present invention has reducing total cholesterol in the body, reduces low-density lipoprotein, the effect of triglyceride reducing and high density lipoprotein increasing.
2. the preparation method of the tea pigment in the claim 1 comprises:
(1) mixes tealeaves and ethanolic soln, soak and backflow.
(2) centrifugal and abandon precipitation.
(3) supernatant is splined on Sephadex LH-20 post, washes post.
(4) collect elutriant, use dichloromethane extraction, abandon water, volatilize methylene dichloride, it is few to obtain impurity, highly active tea pigment powder.
3. the tea pigment in the claim 1 contains theoflavin, thearubigins, theabrownin and catechin.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00116395A CN1328092A (en) | 2000-06-08 | 2000-06-08 | Process for extracting tea pigment and its application in treating hyperlipomia |
| AU2000259752A AU2000259752A1 (en) | 2000-06-08 | 2000-06-19 | Method of obtaining a tea pigment from tea leaves |
| PCT/EP2000/005659 WO2001093886A1 (en) | 2000-06-08 | 2000-06-19 | Method of obtaining a tea pigment from tea leaves |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00116395A CN1328092A (en) | 2000-06-08 | 2000-06-08 | Process for extracting tea pigment and its application in treating hyperlipomia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1328092A true CN1328092A (en) | 2001-12-26 |
Family
ID=4585799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00116395A Pending CN1328092A (en) | 2000-06-08 | 2000-06-08 | Process for extracting tea pigment and its application in treating hyperlipomia |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1328092A (en) |
| AU (1) | AU2000259752A1 (en) |
| WO (1) | WO2001093886A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304586C (en) * | 2003-12-13 | 2007-03-14 | 无锡市世纪生物药业有限公司 | Method for preparing tea pigment |
| CN101473880B (en) * | 2009-01-19 | 2011-06-29 | 中国计量学院 | Method for extracting and separating thearubigins from black tea |
| CN101081844B (en) * | 2006-06-01 | 2011-08-17 | 北京工商大学 | Method for large-batch separating preparation of high-purity theaflavine monomer |
| CN101474313B (en) * | 2009-02-02 | 2012-05-23 | 普洱茶研究院 | Application of theabrownin in pharmacy |
| CN102727743A (en) * | 2011-04-15 | 2012-10-17 | 席宾 | Tea pigment capsule having effects of reducing blood sugar and blood fat and preparation method thereof |
| CN101718744B (en) * | 2009-12-14 | 2012-12-19 | 昆明理工大学 | Functional group content measuring method in theabrownin of Pu'er tea |
| CN104031402A (en) * | 2014-06-17 | 2014-09-10 | 徐宏伟 | Preparation process and application of natural tea dye |
| CN104497622A (en) * | 2014-12-04 | 2015-04-08 | 常州大学 | Method for extracting red brown pigment from tea tree fruits |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002365415C1 (en) * | 2001-11-28 | 2008-12-11 | Nashai Biotech, Llc | Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| US7157493B2 (en) | 2001-11-28 | 2007-01-02 | Nashai Biotech, Llc | Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof |
| US7829132B2 (en) * | 2004-11-03 | 2010-11-09 | Unilever Bestfoods, North America Division Of Conopco, Inc. | Consumable tea composition with antioxidants |
| WO2007065539A1 (en) * | 2005-12-06 | 2007-06-14 | Unilever Plc | Extracts of gynostemma and compositions for reducing blood lipid levels |
| CN103160136A (en) * | 2011-12-08 | 2013-06-19 | 上海蓝普生物科技有限公司 | Extraction method for tea red pigment in green tea |
| CN102911517A (en) * | 2012-10-30 | 2013-02-06 | 中国农业科学院茶叶研究所 | Preparation method and usage of special tea dye for silk |
| JP6375624B2 (en) * | 2014-01-08 | 2018-08-22 | ユーハ味覚糖株式会社 | Post-fermented tea purification composition having LOX-1 inhibitory activity |
| CN111000237A (en) * | 2019-12-25 | 2020-04-14 | 康波 | Dietary composition for dietary intervention of cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN113350310B (en) * | 2021-07-09 | 2022-04-15 | 生命之花(北京)健康管理有限公司 | Tea pigment capsule with blood sugar and blood fat reducing function and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6013780A (en) * | 1983-07-05 | 1985-01-24 | Mitsui Norin Kk | Production of tea catechin compound |
| JPS6230711A (en) * | 1985-08-01 | 1987-02-09 | Furukawa Netsugaku Eng Kk | Drug for alleviating hypercholesterolemia |
-
2000
- 2000-06-08 CN CN00116395A patent/CN1328092A/en active Pending
- 2000-06-19 AU AU2000259752A patent/AU2000259752A1/en not_active Abandoned
- 2000-06-19 WO PCT/EP2000/005659 patent/WO2001093886A1/en active Application Filing
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304586C (en) * | 2003-12-13 | 2007-03-14 | 无锡市世纪生物药业有限公司 | Method for preparing tea pigment |
| CN101081844B (en) * | 2006-06-01 | 2011-08-17 | 北京工商大学 | Method for large-batch separating preparation of high-purity theaflavine monomer |
| CN101473880B (en) * | 2009-01-19 | 2011-06-29 | 中国计量学院 | Method for extracting and separating thearubigins from black tea |
| CN101474313B (en) * | 2009-02-02 | 2012-05-23 | 普洱茶研究院 | Application of theabrownin in pharmacy |
| CN101718744B (en) * | 2009-12-14 | 2012-12-19 | 昆明理工大学 | Functional group content measuring method in theabrownin of Pu'er tea |
| CN102727743A (en) * | 2011-04-15 | 2012-10-17 | 席宾 | Tea pigment capsule having effects of reducing blood sugar and blood fat and preparation method thereof |
| CN102727743B (en) * | 2011-04-15 | 2015-12-16 | 席宾 | There is the tea pigment capsule and preparation method thereof of blood sugar lowering, blood fat effect |
| CN104031402A (en) * | 2014-06-17 | 2014-09-10 | 徐宏伟 | Preparation process and application of natural tea dye |
| CN104031402B (en) * | 2014-06-17 | 2016-02-03 | 徐宏伟 | A kind of preparation technology of tea natural dyestuff and application thereof |
| CN104497622A (en) * | 2014-12-04 | 2015-04-08 | 常州大学 | Method for extracting red brown pigment from tea tree fruits |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001093886A1 (en) | 2001-12-13 |
| AU2000259752A1 (en) | 2001-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1328092A (en) | Process for extracting tea pigment and its application in treating hyperlipomia | |
| JP2762315B2 (en) | A medicament containing Δ5-androslan for treating Alzheimer's disease and modulating the immune system | |
| CN103520618B (en) | A kind of pharmaceutical composition for the treatment of erection disturbance and preparation method thereof and pharmaceutical applications | |
| CN105877567B (en) | The special foot bath of diabetic | |
| CN108514572A (en) | Chinese medicine composition, extract and preparation a kind of anti-inflammatory and that repair skin barrier | |
| CN106860482A (en) | The application of propolis extracted with alcohol | |
| CN109908194A (en) | A kind of drug and preparation method thereof for treating acute/chronic pharyngitis | |
| CN115089622B (en) | Celery exosome composition and preparation method and application thereof | |
| CN102335231A (en) | Chinese medicinal moisturizing cream for treating chloasma as well as preparation method and application thereof | |
| CN1682854A (en) | Oral administration liquor for reducing blood fat | |
| CN100349566C (en) | Medicine for treating eczema and its preparing process | |
| CN106177759A (en) | A kind of compound Chinese medicinal preparation treating angina pectoris and preparation technology thereof | |
| CN105343206B (en) | Compound traditional Chinese medicine extract for reducing blood pressure and blood fat and preparation method thereof | |
| CN105362815A (en) | Traditional Chinese medicine composition for eczema treatment and preparation method of traditional Chinese medicine composition for eczema treatment | |
| CN105168389B (en) | Prepared fleece flower root polysaccharide and its application in liver protection | |
| CN101850031B (en) | Pueraria isoflavone capsule | |
| CN105037447A (en) | Achyranthes bidentata glycopolymer as well as preparation method and application thereof | |
| CN1210057C (en) | Blood lipid capsule and its preparing method | |
| CN100446801C (en) | Ointment for eliminating macula and its preparation method | |
| CN1256098C (en) | Process for preparing livestock animal brain fat composite medicine | |
| CN106075253A (en) | A kind of compound preparation treating diabetes and preparation method thereof | |
| Trung et al. | Ameliorating effects of Bao Mach An liquid extract on serum lipid levels in dyslipidemia animals | |
| CN105362817A (en) | Pharmaceutical composition for treating eczema | |
| CN115844952A (en) | Application of clerodendranthus spicatus extract in preparation of alpha smooth muscle actin inhibitor | |
| WO2015050280A1 (en) | Composition and health functional food for preventing or treating late-onset hypogonadism or andropause syndrome, comprising herbal extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |